| A079 |
Genentech patent anti-IL-8 Biosimilar (Anti-CXCL8 / IL-8 Reference Antibody)
Featured
|
|
|
| A080 |
Roche patent anti-CCN1 Biosimilar (Anti-CYR61 / CCN1 Reference Antibody)
Featured
|
|
|
| A081 |
Dragonfly patent anti-DLL3 Biosimilar （Anti-DLL3 Reference Antibody）
Featured
|
|
|
| A082 |
Begelomab Biosimilar （Anti-DPP4 / CD26 Reference Antibody）
Featured
|
Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy. |
.png)
|
| A083 |
Citatuzumab Biosimilar（Anti-EpCAM / TROP1 / CD326 Reference Antibody）
Featured
|
|
|
| A084 |
MEDI-547 Biosimilar（Anti-EphA2 Reference Antibody）
Featured
|
|
|
| A085 |
Sanofi Aventis patent anti-EphA2 Biosimilar（Anti-EphA2 Reference Antibody）
Featured
|
|
|
| A086 |
Disitamab Biosimilar（Anti-ERBB2 / HER2 / CD340 Reference Antibody）
Featured
|
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)). |
.png)
|
| A087 |
Tisotumab Biosimilar（Anti-F3 / Factor III / Tissue Factor / CD142 Reference Antibody）
Featured
|
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab can be used for the research of solid tumors. |
.png)
|
| A088 |
TNX-832 Biosimilar（Anti-F3 / Factor III / Tissue Factor / CD142 Reference Antibody ）
Featured
|
|
|
| A089 |
Novo Nordisk patent anti-Factor VIII Biosimilar（Anti-F8 / Factor VIII Reference Antibody）
Featured
|
|
|
| A090 |
Emicizumab Biosimilar（Anti-F9 / Factor IX Reference Antibody）
Featured
|
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research. |
|
| A091 |
Sibrotuzumab Biosimilar（Anti-FAP Reference Antibody）
Featured
|
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC). |
.png)
|
| A092 |
VIB9600 Biosimilar(Anti-FcgR2a / CD32a Reference Antibody)
Featured
|
|
|
| A093 |
Cevostamab Biosimilar(Anti- FcRH5 / IRTA2 / CD307e Reference Antibody)
Featured
|
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells. |
.png)
|
| A094 |
DFRF4539A Biosimilar(Anti- FcRH5 / IRTA2 / CD307e Reference Antibody)
Featured
|
|
|
| A095 |
Rozanolixizumab Biosimilar(Anti-FcRn (FCGRT & B2M) Reference Antibody)
Featured
|
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases. |
.png)
|
| A096 |
STX-100 Biosimilar(Anti-Integrin aVb6 (ITGAV & ITGB6) Reference Antibody)
Featured
|
|
|
| A097 |
Abrilumab Biosimilar(Anti-Integrin a4b7 (ITGA4 & ITGB7) Reference Antibody)
Featured
|
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD). |
.png)
|
| A098 |
Batoclimab Biosimilar(Anti-FcRn (FCGRT & B2M) Reference Antibody)
Featured
|
Batoclimab is a human anti-FcRn monoclonal antibody. Batoclimab can be used for the research of autoimmune diseases mediated by pathogenic IgG antibodies. |
.png)
|
| A099 |
1A6 Biosimilar(Anti-FGF19 Reference Antibody)
Featured
|
|
|
| A100 |
HuGAL-F2 Biosimilar(Anti-FGF2 Reference Antibody)
Featured
|
|
|
| A101 |
Burosumab Biosimilar(Anti-FGF23 Reference Antibody)
Featured
|
Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia. |
.png)
|
| A102 |
Lilly patent anti-FGFR-1 Biosimilar(Anti-FGFR1 / CD331 Reference Antibody)
Featured
|
|
|
| A103 |
Aprutumab Biosimilar(Anti-FGFR2 / CD332 Reference Antibody)
Featured
|
Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research. |
.png)
|
| A104 |
Bemarituzumab Biosimilar(Anti-FGFR2 / CD332 Reference Antibody)
Featured
|
Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. |
.png)
|
| A105 |
Vofatamab Biosimilar(Anti-FGFR3 / CD333 Reference Antibody )
Featured
|
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). |
.png)
|
| A106 |
U3-1784 Biosimilar(Anti-FGFR4 / CD334 Reference Antibody)
Featured
|
|
|
| A107 |
Radretumab Biosimilar(Anti-Fibronectin Reference Antibody)
Featured
|
|
.png)
|
| DC66691 |
L19TNF
Featured
|
|
|
